The immunosuppressive tumor microenvironment (TME) supports the development of
tumors and limits tumor immunotherapy, including hematological malignancies …

Immunotherapy plays a key role in cancer treatment, however, responses are limited to a
small number of patients. The biological basis for the success of immunotherapy is the …

Background: Immunotherapy has demonstrated its potential to improve the prognosis of
patients with hepatocellular carcinoma (HCC); however, patients' responses to …

The breast cancer tumor microenvironment (TME) is dynamic, with various immune and non-
immune cells interacting to regulate tumor progression and anti-tumor immunity. It is now …

Tumor-associated macrophages (TAMs) are integral to the tumor microenvironment (TME),
influencing cancer progression significantly. Attracted by cancer cell signals, TAMs exhibit …

Gastric cancer (GC) is one of the most common gastrointestinal malignancies worldwide. In
the past decade, with the development of early diagnostic techniques, a clear decline in GC …

Squamous cell cancer of the head and neck (HNSCC) is the sixth most common cancer and
is associated with significant morbidity and mortality. The tumor microenvironment for …

Immunotherapies have revolutionized the landscape of cancer treatment. Regulatory T cells
(Tregs), as crucial components of the tumor immune environment, has great therapeutic …

Women worldwide are more likely to develop breast cancer (BC) than any other type of
cancer. The treatment of BC depends on the subtype and stage of the cancer, such as …

Immunotherapy for immune response has ushered in a new era of cancer treatment. In
recent years, new immunotherapeutic agents have been introduced into clinical trials and …